Bill & Melinda Gates Foundation Trust
Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people's health and giving them the chance to lift themselves out of hunger and extreme poverty. In the United States, it seeks to ensure that all people - especially those with the fewest resources - have access to the opportunities they need to succeed in school and life. Based in Seattle, Washington, the foundation is led by CEO Jeff Raikes and Co-chair William H. Gates Sr., under the direction of Bill and Melinda Gates and Warren Buffett.
-
GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 (sotrovimab) for the Early Treatment of COVID-19
-
GSK (GSK) and Vir Biotechnology (VIR) Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19
-
GSK and Vir Biotechnology Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19
-
GSK (GSK) to support manufacture of Novavax' (NVAX) COVID-19 vaccine
-
Eli Lilly & Co. (LLY), Vir Biotech (VIR) & GlaxoSmithKline (GSK) Report Positive Topline Data from Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
-
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
-
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
-
GlaxoSmithKline (GSK), Vir Biotechnology Inc. (VIR) Submit Emergency Use Request with FDA for VIR-7831 for the Early Treatment of COVID-19
-
GSK and Vir Biotechnology Announce Submission of Emergency Use Authorization Request to FDA for VIR-7831 for the Early Treatment of COVID-19
-
Vir Biotechnology (VIR) Gains 50% as VIR-7831 Reduces Hospitalization and Risk of Death from COVID-19
-
Vir Biotechnology Inc. (VIR) and GSK Provide Update on NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
-
Vir Biotechnology and GSK Provide Update on NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
-
Moderna (MRNA) Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines
-
Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines
-
Zika vaccine race spurred by crisis and profit potential
-
Zika vaccine race spurred by crisis and profit potential
-
Zika vaccine race spurred by crisis and profit potential
-
Zika vaccine race spurred by crisis and profit potential
-
Zika vaccine race spurred by crisis and profit potential
-
Zika vaccine race spurred by crisis and profit potential
-
Zika vaccine race spurred by crisis and profit potential
-
Zika vaccine race spurred by crisis and profit potential
-
Zika vaccine race spurred by crisis and profit potential
-
Zika vaccine race spurred by crisis and profit potential
-
Zika vaccine race spurred by crisis and profit potential
-
Zika vaccine race spurred by crisis and profit potential
-
Zika vaccine race spurred by crisis and profit potential
-
Zika vaccine race spurred by crisis and profit potential
-
Zika vaccine race spurred by crisis and profit potential
-
Zika vaccine race spurred by crisis and profit potential
-
Zika vaccine race spurred by crisis and profit potential
-
Zika vaccine race spurred by crisis and profit potential
-
Zika vaccine race spurred by crisis and profit potential
-
Zika vaccine race spurred by crisis and profit potential
-
Zika vaccine race spurred by crisis and profit potential
-
Zika vaccine race spurred by crisis and profit potential
-
Agenus (AGEN) Shares Circuit Breaker Following 25% Surge as Glaxo Says RTS,S Vaccine Cut Risk of Malaria
